H
eart failure (HF) with preserved ejection fraction (HFpEF) is a huge public health problem. 1 There is no proven effective treatment. Patients with HFpEF are not able to engage in physical activity without developing symptoms of dyspnea and fatigue. This diminishes quality of life and is associated with increased mortality. 1, 2 To perform physical activity, we increase O 2 consumption (Vo 2 ). Oxygen transport is accomplished through convective and diffusive processes. Convective transport involves 2 steps: introduction of O 2 into the lungs (alveolar ventilation) and transport from the lungs to the periphery in the circulation (cardiac output [CO] ). Diffusive O 2 transport describes 2 additional steps: movement of O 2 across the alveolar-pulmonary capillary interface in the lung and unloading of O 2 from hemoglobin in skeletal muscle capillaries (D M ), where mitochondria consume it to make ATP. Impairments in any or several of these steps can constrain the ability of the body to increase Vo 2 and thus perform activity.
When patients with HF display low peak Vo 2 , it is often assumed that this reflects a deficit in CO. However, according to the Fick principle, Vo 2 is equal to the product of CO and the arterial-venous O 2 content difference (AVO 2 diff). More than 20 years ago, Wilson and colleagues 3 made the remarkable observation that 1/4 of patients with severe HF and reduced ejection fraction (HFrEF) actually display normal leg blood flow during exercise. Despite adequate convective O 2 delivery, these patients developed profound leg fatigue and an accelerated increase in venous lactate, indicating a switch to anaerobic glycolysis. The patients were less able to increase AVO 2 diff during exercise, and this drove their low peak Vo 2 rather than poor CO. 3 More recently, Esposito et al 4 have shown that this peripheral limitation is driven primarily by low D M , and the importance of the periphery in HFrEF is now well established. 3, 4 The story in HFpEF is much the same. For years it was believed that exercise limitation was exclusively caused by inadequate ventricular filling from diastolic dysfunction. 5 But then it was found that, despite normal resting CO, patients with HFpEF display significant limitations in the ability to augment CO in response to exercise. [6] [7] [8] Others then reported that many patients with HFpEF also display limitations in the ability to increase AVO 2 diff, much like what is seen in HFrEF. [9] [10] [11] [12] [13] However, AVO 2 diff is determined by both convective and diffusive O 2 transfer, and the more specific role of D M in HFpEF has remained unclear.
In this issue of Circulation, Houstis and colleagues 14 present an interesting new theoretical analysis emphasizing the importance of both central and peripheral contributors in HFpEF. The authors retrospectively examined data from 79 patients with HFpEF and 55 controls. Using expired gas analysis and arterial and mixed venous blood sampling, they examined individual steps of the O 2 pathway during peak exercise. Some components were directly measured, including alveolar venti-lation and CO. Others, such as lung diffusion, D M , and mitochondrial respiration, were not directly measured but were estimated using a number of simplifying assumptions. 14 The authors found that peak Vo 2 was reduced by 34% in patients with HFpEF compared with controls. 14 This was coupled with reduced O 2 entry through the lungs, manifest as 36% and 31% reductions in alveolar ventilation and pulmonary O 2 diffusion, respectively. Convective O 2 delivery from lungs to tissues was reduced by 31% mainly because of a 27% reduction in CO but also a 5% reduction in hemoglobin. Peak exercise AVO 2 diff was reduced in HFpEF but only by 8%. This might suggest at first glance that the periphery is less important.
However, when CO drops, there is greater time available for O 2 diffusion in the capillaries. 7 This finding led the authors to propose that AVO 2 diff should have been even higher in the group with HFpEF.
14 To adjust for this, they plotted CO versus AVO 2 diff during peak exercise in their control group and then compared the observed AVO 2 diff relative to CO in the group with HFpEF with what would be expected based on their control group curve. This adjustment inflated the AVO 2 diff deficit dramatically, such that it became 26% lower in the group with HFpEF.
Although this adjustment makes sense for the reasons noted, an alternative argument could be made. Muscle perfusion is tightly coupled to O 2 requirements in man. 15 The signals that regulate increased CO as muscle O 2 demand increases are as yet unresolved, yet it is clear that as venous O 2 content drops (and AVO 2 diff increases), the body responds by providing more blood flow. 7, 15 The authors conclude that AVO 2 diff should have been higher in HFpEF, but what if the heart was unable to respond to reduction in venous O 2 with sufficient increase in CO? If this were true, then the true CO deficit would have been even higher. The circularity of the Fick principle is problematic here, and this dilemma cannot be resolved given the cross-sectional nature of this study. 14 The authors found that the deficit in AVO 2 diff was related to a 36% reduction in D M in HFpEF.
14 This observation is novel and important. D M was calculated assuming that muscle venous O 2 tension was equal to that in the pulmonary artery. However, this is not the case because the pulmonary artery sample contains mixed venous blood from the rest of the body that contains much higher O 2 content when compared with the effluent blood from the femoral veins. To optimally distribute blood flow during exercise, there must be vasodilation to areas in need, such as skeletal muscle, and sympathetically mediated vasoconstriction to nonexercising areas, such as viscera and adipose. Regional vasodilation in skeletal muscle is mediated in part by NO and prostaglandin-induced vasodilation. 16 Patients with HFpEF have impaired NO availability, particularly in the microvasculature, so this might contribute to the impairment in D M . 6 Patients with HFpEF are also commonly obese, and it could be that obligate perfusion to excess fat mass might cause an effective macrovascular shunt that diminishes proper matching of flow to metabolismthis could also contribute to a lower AVO 2 diff. 17, 18 Conversely, microvascular shunting may occur within skeletal muscle in HFpEF, especially when there is increased intramuscular fat and reduced capillary density, as recently reported. 11, 12 Further study is needed to better understand the mechanisms of and treatment for D M impairment in HFpEF.
Houstis and colleagues 14 propose that the O 2 pathway enables ascertainment of the causes of exercise intolerance in HFpEF, but we cannot infer causation from correlation. The differing peak workloads achieved in controls and HFpEF are especially confounding. As exercise intensity increases, there is greater enhancement in convective O 2 transport, as well as O 2 diffusion, in both the lungs and skeletal muscle. 19 If patients with HFpEF would have been able to exercise to higher load, would they have been able to achieve a higher D M ? The same question can be raised with all components of the O 2 pathway. Controls were required (by design) to display peak Vo 2 that was >90% predicted, whereas HFpEF were required to display values <80%.
14 Therefore, differences in peak Vo 2 , as well as the associated deficits in O 2 pathway components, are to some extent tautological. It would be interesting to evaluate whether similar differences would exist between cases and controls at matched workloads.
The authors found that the majority of patients with HFpEF (97%) displayed limitations in multiple components of the O 2 pathway.
14 To extend the data further, they conducted a theoretical analysis to explore what the expected boost in peak Vo 2 might be if they could fix 1 or more components of the O 2 pathway while holding others constant. After accounting for the hypothesized reduction in AVO 2 diff from increased perfusion, isolated improvements in CO were predicted to lead to a relatively modest increase in peak Vo 2 . Although this may be the case, it is important to acknowledge that these predictions are speculative based on highly theoretical modeling equations without in vivo human data. It is unknown to what extent increases in CO would truly compromise O 2 diffusion in the periphery in HFpEF when O 2 demand is high, such as during exercise. Indeed, single-leg exercise allows for increased muscle blood flow that improves Vo 2 relative to muscle mass, without dramatically compromising D M in patients with HFrEF. 4 These questions require further testing using appropriately controlled interventional experiments to be answered.
The biggest boost in peak Vo 2 in the authors' analysis was observed by improving D M , again supporting an important role of the periphery, and there was synergy from improving multiple components together, which was highly dependent on the nature and magnitude of deficits in the O 2 pathway.
14 Although the analytic modeling performed is elegant and intellectually appealing, it seems unlikely that we can accurately estimate the effects of correcting a single impairment in the O 2 pathway while expecting others to remain constant-a limitation that the authors acknowledge. It does seem reasonable to conclude that the plurality of abnormalities observed in most patients supports therapies targeting multiple components of the O 2 pathway, such as exercise training or inorganic nitrites, as are currently being tested. 20 Houstis et al 14 ponder whether O 2 pathway analysis might form the basis for a new taxonomy of HFpEF, with the idea of personalizing the deficits. Although this goal is laudable, it may be problematic using this approach for several reasons. First, diseases caused by a variety of different pathologies may converge to cause similar limitations in the periphery. Each of these pathologies is likely just as complex and heterogeneous as HFpEF. Examples include not only HFrEF, as discussed, but other chronic diseases ranging from aortic stenosis, pulmonary arterial hypertension, and COPD to cancer. If we just relied on O 2 pathway analysis alone, we might lump these patients together and ignore the specific cardiac, pulmonary, or vascular lesions that initially caused the problem. In other words, this sort of complexity is ubiquitous in human disease; it is not unique to HFpEF.
The authors 14 imply in the discussion that their analysis was undertaken to link HF symptoms to their cause. But HF symptoms are not equivalent to peak aerobic capacity. Indeed, most patients with HFpEF never achieve levels of Vo 2 attained with maximal exercise testing during everyday life. The authors' analysis also assumes that all features of exercise intolerance can be simplified into terms of O 2 transport. However, this approach neglects the impact of other important components in HFpEF, such as elevated filling pressures, which may alter lung mechanics, gas diffusion, respiratory muscle function, and right ventricular-pulmonary artery coupling, and are associated with symptoms, exercise capacity, and clinical outcomes. 8, [19] [20] [21] Indeed, it would be hard to imagine how peripheral impairments would cause pulmonary hypertension, right ventricular dysfunction, or the development of pulmonary edema in patients with acutely decompensated HF.
Thus, can we assume that the factors restricting O 2 consumption at the limits of peak endurance explain the symptoms that develop during everyday activities for patients? Probably not, but that doesn't mean that targeting these limitations won't be helpful. Why do patients with HFpEF feel so poorly when they exert themselves? The answer is the same in HFpEF as it is in HFrEF and many other disorders: it is complicated. The novel and important insights provided by Houstis and colleagues 14 in their elegant study have vertically advanced our understanding to make it significantly less complicated while suggesting important new hypotheses that can be tested in the years to come.
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